Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-05-12

Study Completion Date

2020-11-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (SARS-CoV-2) from these pneumonia patients and developed a real-time reverse transcription PCR (real-time RT-PCR) diagnostic assay.

Given no specific antiviral therapy for COVID-19 and the ready availability of plitidepsin as a potential antiviral agent, based on pre-clinical studies, this randomized, parallel and proof of concept trial will evaluate the safety of three doses of plitidepsin in patients hospitalized with COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection

NCT04784559

COVID-19 Infection

TERMINATED PHASE3

A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)

NCT04439071

Pneumonia COVID-19 Coronavirus

TERMINATED PHASE2/PHASE3

Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)

NCT04575584

Coronavirus Disease (COVID-19)

TERMINATED PHASE2/PHASE3

Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002)

NCT04575597

Coronavirus Disease (COVID-19)

COMPLETED PHASE2/PHASE3

First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.

NCT04535167

Viral Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In December 2019, a new infectious respiratory disease emerged in Wuhan, China. The agent that caused this pneumonia was identified as a new virus in the Coronaviridae family (SARS-CoV-2) and the clinical symptomatology associated with the virus has been named COVID-19. COVID-19 is currently a public health emergency.

Plitidepsin is an authorized drug in Australia for the treatment of multiple myeloma. Antiviral activity of plitidepsin has been analyzed in a human hepatoma cell line infected with the HCoV-229E-GFP virus, a virus similar to the SARS-CoV-2 virus.

Taking into account that the available safety data from plitidepsin comes from patients with solid tumors that received treatment with a regimen of administration of plitidepsin for 5 consecutive days, we propose a multicenter, randomized, proof-of-concept clinical trial to assess the safety profile of 3 different dose levels of plitidepsin administered three consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital admission.

This study aims to assess safety and toxicity profile and also preliminary efficacy of plitidepsin at each dose level administered according to the proposed administration scheme in patients with COVID-19 who require hospital admission. Main objective is to select the recommended dose levels of plitidepsin for a future phase II / III efficacy study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.

All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:

* Diphenhydramine hydrochloride 25 mg iv or equivalent.
* Ranitidine 50 mg iv or equivalent.
* Dexamethasone 8 mg iv.
* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.
* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plitidepsin 1.5 mg/day

Plitidepsin 1.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.

All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:

* Diphenhydramine hydrochloride 25 mg iv or equivalent.
* Ranitidine 50 mg iv or equivalent.
* Dexamethasone 8 mg iv.
* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.
* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.

Intervention Type DRUG

Plitidepsin 2.0 mg/day

Plitidepsin 2.0 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.

All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:

* Diphenhydramine hydrochloride 25 mg iv or equivalent.
* Ranitidine 50 mg iv or equivalent.
* Dexamethasone 8 mg iv.
* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.
* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.

Intervention Type DRUG

Plitidepsin 2.5 mg/day

Plitidepsin 2.5 mg/day will be IV infused through a pump device over 1 hour and 30 minutes, 3 consecutive days.

All patients must receive the following prophylactic medications 20-30 minutes before the infusion of plitidepsin:

* Diphenhydramine hydrochloride 25 mg iv or equivalent.
* Ranitidine 50 mg iv or equivalent.
* Dexamethasone 8 mg iv.
* Ondansetron 8 mg i.v. 15 minutes infusion or equivalent.
* Ondansetron 4 mg p.o. administered every 12 hours until 48 hours after the last administration of plitidepsin.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient who agrees to participate in the study by signing the informed consent.
2. Men and women (non-pregnant) aged ≥18 years.
3. COVID-19 infection confirmed by PCR obtained from nasopharyngeal exudate or sample from the lower respiratory tract.
4. Patients who require hospitalization for COVID-19.
5. Symptom onset at most within 10 days prior to study inclusion.
6. Men and women with reproductive capacity should agree to use highly effective contraceptive methods during their participation in the study and in the 6 months following the last administration of plitidepsin.
7. In addition, women participating in the study with reproductive ability must have a negative pregnancy test at enrollment.

Exclusion Criteria

1. Patients participating in some other clinical trial for COVID-19 infection.
2. Patients who are receiving treatment with antivirals, interleukin 6 receptor inhibitors or immunomodulatory drugs for COVID-19.
3. Patients who are receiving treatment with chloroquine and derivatives.
4. Evidence of multi-organ failure.
5. Patients who require support with mechanical ventilation (invasive or non-invasive) at the time of inclusion.
6. D-dimer\> 4 x UNL.
7. Hb \<9 g / dL.
8. Neutrophils \<1000 / mm3.
9. Platelets \<100,000 / mm3.
10. Lymphopenia \<800 / μL.
11. GOT / GPT\> 3 X UNL.
12. Bilirubin\> 1 X UNL.
13. CPK\> 2.5 X UNL.
14. Creatinine clearance \<30ml / min.
15. Troponin elevation\> 1.5 x ULN.
16. Clinically relevant heart disease (NYHA\> 2).
17. Clinically relevant arrhythmia or previous history / presence of prolonged QT-QTc ≥ 450 ms.
18. Pre-existing neuropathies of any type ≥ grade 2.
19. Hypersensitivity to the active substance or to any of its excipients (macrogol glycerol ricinoleate and ethanol).
20. Patients who require or are being treated with potent CYP3A4 inhibitors and inducers.
21. Patients who for any reason should not be included in the study according to the evaluation of the research team.

Minimum Eligible Age

18 Years